General Information of Drug (ID: DM19R28)

Drug Name
ADC-01 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
TTD Drug ID
DM19R28

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID26077642-Compound-Vif2 DMYXIS7 N. A. N. A. Patented [3]
PMID26077642-Compound-Vif1 DMS9KCF N. A. N. A. Patented [3]
ADC-03 DM21I35 Solid tumour/cancer 2A00-2F9Z Preclinical [2]
P22077 DMD8JIC Inflammation 1A00-CA43.1 Preclinical [4]
HBX19818 DM6GSI1 Solid tumour/cancer 2A00-2F9Z Preclinical [5]
P5091 DMGIR3F Solid tumour/cancer 2A00-2F9Z Preclinical [6]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Herpesvirus ubiquitin-specific protease (HAUSP) TTXU3EQ UBP7_HUMAN Inhibitor [2]

References

1 Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
2 Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579.
3 Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
4 P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6. Aging (Albany NY). 2020 Jun 9;12(11):10969-10982.
5 Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8(8):2286-95.
6 USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol. 2017 May 1;131:29-39.